cyrilzakka/clinical-trials huggingface dataset:
Investigating Kinematic and Electromyographic Changes After SCI and Their Relation to Clinical and Functional Outcome

The study aims at discerning specific gait patterns and elucidating locomotor control of spinal cord injured patients in order to find sensitive kinematic and electromyographic outcome measures that are able to reveal information on underlying mechanisms of normal and aberrant gait control and its recovery over time. These measures may also be used to compare the outcome across different neurological disorders.


Eligibility Criteria:
Inclusion Criteria:

Patients: We will monitor patients who were admitted to the Spinal Cord Injury Center of the University Hospital Balgrist. We will record patients with various aetiologies, grades of impairment and types of spinal cord lesions. Patients need to have minimal voluntary motor capacities: the motor scores of the key muscles according to the ASIA classification (www.asia-spinalinjury.org) should be at least 3 for extensor muscles and 2 for flexor muscles. Written informed consent is required. Control subjects: Healthy subjects, written informed consent.

Exclusion Criteria:

Patients: Comorbidities which influence or inhibit gait or upper-limb motion (e.g. peripheral nerve lesions). Orthostatic problems that greatly impair upright body position. Mental illness, cognitive impairments. Control subjects: neurologic disease, walking disabilities, mental illness, cognitive impairments
Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients

Contrast-Induced Nephropathy (CIN) can occur when patients with pre-existing kidney problems undergo procedures that use iodinated contrast media, such as cardiac catheterizations. RenalGuard Therapy was developed to enable the patient to clear the contrast out of their kidney before it can do significant damage. This study aims to enroll patients with increased risk of developing CIN who are scheduled for a cardiovascular catheterization. Patients will be randomized to either RenalGuard therapy or standard therapy.


Eligibility Criteria:
Inclusion Criteria:

* Male or non-pregnant female equal or greater than the age of 18 years old and is able to provide informed consent.
* Subject is scheduled to undergo an elective catheterization procedure
* Hemodynamically stable
* At increased risk of developing CIN
* Subject has agreed to all follow-up testing.

Exclusion Criteria:

* Class 4 Congestive Heart Failure (CHF)or a documented left ventricular ejection fraction \< 30%
* Is anuric or has undergone renal replacement therapy within the past month, or has a known inability to have a Foley catheter placed.
* Subject has been hospitalized or treated medically for any change in renal function over the past week (i.e. dialysis, etc.), or a significant change in renal function is noted at time of screening.
* Has documented severe Aortic Stenosis.(Note: Subjects who have undergone successful replacement or repair of their aortic valve are not excluded.)
* Currently has a known clinically significant electrolyte imbalance or clinically significant arrhythmias which compromise subject's hemodynamic state.
* Patient has severe anemia (hemoglobin \< 8.0 g/dL) at screening
* Has received contrast within 10 days of procedure or has a planned additional cardiac or renal or other major surgical procedure within the 7 day follow-up period.
* Has ruled in for a Serious Heart Attack within 48 hours of the planned procedure
* Has documented respiratory insufficiency as evidenced by an oxygen saturation of \< 90% on room air assessed on day of procedure.
* Planned addition, discontinuation or dose adjustment of nephrotoxic drugs
* Subject has a known hypersensitivity to furosemide and/or the contrast agent being used.
* Subject is currently, plans, or has been enrolled in another clinical study involving use of an investigational drug or device within the prior 30 days.
* Subject is pregnant or breastfeeding.
* Subject is unable to provide informed consent.
Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma

The purpose of this study is to compare effects of erlotinib and pemetrexed as maintenance therapy for lung adenocarcinoma. Primary Outcome is the progression free survival (PFS). Based on prediction of different potential benefit groups, this study may help the oncologist to optimize and improve the maintenance therapy plan for lung adenocarcinoma.


Eligibility Criteria:
Inclusion Criteria:

* Histologically or cytologically diagnosed stage III/IV Lung Adenocarcinoma;
* Age of 18-75years; Gender Not Required;
* Received systemic clinical examination, including chest X-ray, abdomen B ultrasound, head CT scan, radionuclide bone scan;
* Received cisplatin chemotherapy for 4 cycles before this study, the curative effect of chemotherapy is SD or above SD (efficacy evaluation time is 21 days, if it is SD, then the longest diameter of target lesions shall not increase);
* Adequate hematologic, renal, and hepatic function, Specific index as follows: liver function: S-Bilirubin ≤1.5 ULN ; Transaminase≤2 ULN. renal function: S-Creatinine ≤1.2 ULN; blood urea nitrogen ≤1.2 ULN . ULN: upper normal limit. Marrow Hemopoietic Function: WBC≥4.0×10\^9/l, ANC≥2.0×10\^9/l platelet count ≥100×10\^9/l, Hb≥100 g/l;
* ECOG PS 0-2,Life expectancy ≥ 3 months; endure more than two cycle chemotherapy;
* The patients have explicit lung tumor lesions and the lesions were measurable; (According to the standard of RECIST1.1, they should have at least one of accurately measurable lesions with the largest diameter ≥ 10mm by spiral CT, MRI);
* No history of serious drug allergy;
* Informed consent should be obtained before treatment.

Exclusion Criteria:

* Not histologically or cytologically diagnosed as Lung Adenocarcinoma
* The age of \>75 years or \<18 years.
* Major organ dysfunction and Serious Heart Disease (congestive heart-failure, incontrollable high-risk arrhythmia, unstable angina, alular disease, myocardial infarct and Resistant hypertension,);
* Serious complications and investigator consider it is unsuited enrolling;
* Pregnant or lactating women;
* Allergic to research drug;
* Received cisplatin chemotherapy for 4 cycles before this study, the curative effect of chemotherapy is PD
Trial of New Pretreatment Method in Transnasal Endoscopy

This study designed for compare efficacy of following two anesthetic method for transnasal endoscopy

* "Catheter-free method"
* "Catheter-insertion method"

1. Check of the medical history (both method)

   1. underlying systemic disease
   2. drug allergy
   3. anticoagulant or antiplatelet use
2. Premedication (both method)

   1. taking premedication contain dimethylpolysiloxane, pronase, sodium bicarbonate for improved endoscopic visualization
   2. spraying naphazolin acetate into nasal cavity for decrease secretion
3. Different anesthetic method for transnasal endoscopy

   1. "Catheter-free method" : spraying epinephrine into nasal cavity
   2. "Catheter-insertion method" : spraying both epinephrine and lidocaine into nasal cavity

Eligibility Criteria:
Inclusion Criteria:

* Routine check-up patients

Exclusion Criteria:

* nasal operation, an allergy, a possibility of hemorrhage
The Effect of PERT on Patients Undergoing Pancreaticoduodenectomy

A comprehensive perioperative nutrition management plan for pancreaticoduodenectomy, primarily based on pancreatic enzyme replacement therapy (PERT). A prospective randomized controlled study was conducted to comprehensively analyze the perioperative nutritional status of patients undergoing pancreaticoduodenectomy, with the aim of exploring:

1. The effect of PERT on postoperative complications and physiological status after pancreaticoduodenectomy;
2. The efficacy of PERT treatment on clinical symptoms, nutritional indicators, and quality of life (QOL) related to pancreatic exocrine dysfunction (PEI) after pancreaticoduodenectomy;
3. The personalized full process nutrition management strategies based on risk factor stratification.


Eligibility Criteria:
Inclusion Criteria:

* Gender unlimited, 18-80 years old;
* Patients undergoing pancreaticoduodenectomy due to various benign or malignant diseases;
* Voluntary testing with informed consent.

Exclusion Criteria:

* Pregnant women and lactating women
* Patients with distant metastasis based on tumor staging before surgery;
* Tumor recurrence;
* Refuse to sign the consent form.
Hypnosis and MEOPA in Regional Painful Syndrome Complex

Relation between hypnosis and MEOPA on algodystrophy.


Eligibility Criteria:
Inclusion Criteria:

* Regional Painful Syndrome Complex

Exclusion Criteria:

* deaf people
Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns

This study will assess the impact of a systematic bladder health screening and disease education regimen as well as the implementation of a referral process on the quality of life of multiple sclerosis patients with bladder dysfunction.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of relapsing-remitting multiple sclerosis and currently being treated by study doctor

Exclusion Criteria:

* Diagnosis of primary-progressive, secondary-progressive, or progressive-relapsing multiple sclerosis
Effects of Hyperoxia on Open Heart Surgery

Patients undergoing Open Cardiac Surgery will be randomized into two groups. Group I will be ventilated with 40% Fio2 during induction, surgery and in Postoperative care unit. Group II will be ventilated with 100% Fio2 during induction and with 60-70% ( determined according to the arterial blood gas sample results) during surgery and in Postoperative care unit.

Hemodynamic parameters ( systolic arterial pressure, diastolic arterial pressure, heart rate ), Arterial blood gas samples ( PaO2, PaCO2, pH, Oxygen saturation, Lactate), and pre and post cardiopulmonary bypass Superoxide dismutase and malonyl aldehyde levels.


Eligibility Criteria:
Inclusion Criteria:

* ASA II-III
* Patients with EF higher than 50%.
* patients undergoing elective open heart surgery on pump ( CABG, Valve Replacement)

Exclusion Criteria:

* patients with Diabetes Mellitus
* patients with COPD
* Patients with Cerebral Vascular Disease
* Patients with hypoxia in Arterial blood gas samples ( PaO2 lower than 80 mmHg) and hypercarbia (PaCO2 higher than 45 mmHg)
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help the study of cancer in the future.

OBJECTIVES:

I. Collect malignant, borderline malignant neoplasms, and related biological specimens from Children's Oncology Group institutions for cases in which there is no disease-specific biologic protocol.

II. Provide a repository for long-term storage of malignant, borderline malignant neoplasms, and related biological specimens from these patients.

III. Make specimens available to qualified researchers to understand the biology of cancer in these patients.

OUTLINE:

Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.

Eligibility Criteria:
Inclusion Criteria:

* Meets any of the following criteria:

  * Diagnosed with primary neoplasm
  * Developed a second malignant neoplasm
  * Any diagnoses having an ICD-O Morphology Code ending in 1, 2, or 3 as listed in the International Classification of Disease for Oncology, Third Edition
* Must have biological specimens including solid tumors and leukemias available

  * Solid tumors meeting the following criteria:

    * Snap frozen primary tumor OR OCT embedded primary tumor OR formalin fixed (block or tissue in formalin) primary tumor AND at least 10 unstained paraffin slides for NIH Mandated QC (tumors that have undergone central pathology review are allowed)

      * Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
  * Pleural fluid or cytologic specimens meeting the following criteria:

    * At least 1 mL of fluid and at least 2 unstained cytospin slides (or 2 unstained smears)

      * Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
  * ALL/AML

    * 3-6 mL of bone marrow aspirate and 10 mL of whole blood
* Not eligible for disease-specific biology or banking protocol
Clinical Study of Lyophilized Plasma in Patients With Liver Disease

A multi-center, phase 2, randomized, controlled study of the effect of lyophilized plasma in patients with liver disease.


Eligibility Criteria:
Inclusion Criteria:

1. Male or female patients at least 18 years of age.
2. Patients with liver disease.
3. Patients who have need for plasma therapy for a surgical or an invasive procedure or who have evidence of bleeding.
4. Patients with an elevated international normalized ratio due to liver disease.
5. Patients who have given written informed consent or for whom written informed consent has been obtained from the patient's legal representative on their behalf.
6. Patients able and willing to comply with the procedures laid out in the study protocol.

Exclusion Criteria:

1. Patients who are clinically unstable.
2. Patients who have received mediations that could interfere with results of laboratory testing.
3. Patients who have congenital or acquired coagulopathies of non-hepatic origin.
4. Pregnant or nursing women.
5. Active illicit drug use.
6. Patients participating in another clinical treatment study currently or during the past 1 month prior to study inclusion.
7. Patients previously enrolled in this study.
A Post Market Device Study for the Treatment of Acne

To evaluate the safety and efficacy of the Cutera laser system for the treatment of acne vulgaris.


Eligibility Criteria:
Inclusion Criteria:

1. Female or Male, Fitzpatrick Skin Types I-VI, 16 to 60 years of age (inclusive).
2. Has clinically diagnosed acne vulgaris of severity grade 3 - 4 (moderate to severe) on the face based on photographic review by expert dermatologist grader(s) using the Investigator's Global Assessment Scale.
3. Has ≥ 10 inflammatory acne lesions on the face as determined by the Investigator (or qualified designee).
4. Subject (and parent or legal guardian if subject is a minor under age 18) must be able to read, speak, and understand English and sign the Informed Consent Form.
5. Willing and able to adhere to the treatment and follow-up schedule and pre/post-treatment care instructions.
6. Willing to have very limited sun exposure (including avoiding tanning booths, sun lamps, sunbathing) and use an investigator approved sunblock or sunscreen of SPF 30 or higher on the face every day for the duration of the study, including the follow-up period.
7. Must maintain the same acne treatment regimen, including topical and systemic medications for at least 2 weeks prior to enrollment, and for the duration of the study, including the follow-up period unless approved by the Investigator.
8. Willing to have photographs taken of the face and agree to the use of photographs for presentation, educational or marketing purposes.
9. Agree to not undergo any other procedure(s) or add any new treatment modalities in the target area during the study unless approved by Investigator.
10. Willing to use investigator approved skincare topicals and follow investigator approved skincare regimen for the duration of the study.

Exclusion Criteria:

1. Has clinically diagnosed acne vulgaris of severity grade 0, 1, 2 (clear, almost clear, mild) on the face based on photographic review by expert dermatologist grader(s) using the Investigator's Global Assessment Scale.
2. Prior treatment to the target area during participation in a clinical trial of another device or drug within 1 month (30 days) prior to study participation.
3. Still healing from another treatment in the target area according to investigator's discretion.
4. Currently pregnant or planning on becoming pregnant anytime during the duration of the study.
5. Excessive facial hair (e.g., beards, sideburns, moustaches, etc.) that may preclude treatments, photos, or accurate acne lesion assessments in the target area.
6. Currently undergoing treatment for skin cancer in the target area or undergoing systemic chemotherapy for the treatment of cancer.
7. As per the Investigator's discretion, any physical, mental or medical condition which might make it unsafe for the subject to participate in this study or might interfere with patient's participation in the full study protocol.
8. Known hypersensitivity to, history of allergic reaction to, or contraindication to Pro-Nox or mild oral anti-anxiety or pain medication, if administered.
Effects of Embryogen in RIF Patients

The purpose of this study was to investigate the potential effects of Granulocyte-Macrophage Stimulating-Colony Factor (GM-CSF) supplementation in embryo culture for patients with repeated implantation failure (RIF)

60 patients with repeated implantation failure were involved.

RIF was defined as patients failed to conceive (beta-hCG \< 5 mIU/mL) after at least 03 embryo transfers (fresh and frozen) with 06 top quality embryos or more.

Ovarian stimulation was performed using GnRH antagonist protocol. All matured oocytes were inseminated by ICSI. Injected oocytes were cultured in medium supplemented with 2ng/ml of GM-CSF (Embryogen, Origio) until day of transfer. Embryo evaluation was performed at ﬁxed time points of 18 and 44 hour after fertilization. Embryo transfer was performed 2 days after ovum retrieval.

Luteal-phase support was provided using progesterone gel (Crinone 8% 90 mg, twice a day; Merck Serono) and estradiol per os (Valiera 2mg, twice a day; Laboratorios Recalcine). Serum hCG was measured 16 days after oocyte retrieval, and if positive, an ultrasound scan was performed at gestational weeks 7 and 12.

Eligibility Criteria:
Inclusion Criteria:

* Normal ovarian reserve (AMH \> 1.1 ng/ml)
* Regular menstrual cycle (25 - 34 days)
* Clear informations about at least 3 latest IVF/ET
* Fresh embryo transfer in this cycle
* Endometrial thickness of 10 mm or more

Exclusion Criteria:

* Undergo oocyte donation or in vitro maturation (IVM) cycles
* Using frozen or surgically retrieved sperm
* Adenomyosis, Uterine anomaly, uterine fibroid, hydrosalpinges
* In participation in other studies/interventions
Examınatıon of Sports Injury Anxıety Level and Sports Injury Preventıon Awareness of Unıversıty Students Partıcıpatıng in Sports

This study aimed to evaluate the concerns of university students who are involved in sports on more than one subject related to sports injuries (anxiety of losing ability, anxiety of suffering, anxiety of losing social support, etc.). In addition, in this study, the awareness of protection from sports injuries was evaluated in order to minimize sports injuries and create awareness of injury prevention, based on the idea that the athlete will be injured less with less anxiety in sports life.

Regardless of the sport branch, athletes are likely to encounter many injury stories during their active sports life. Stories of sports injuries cause anxiety in athletes. Therefore, sports injury prevention awareness is important. This study aimed to evaluate and compare the anxiety about sports injuries and sports injury prevention awareness of university students studying in different faculties and practicing regular sports. Personal Information Form, Sports Injury Anxiety Scale (SIAS) and Sports Injury Prevention Awareness Scale (SIPAS) were used. There was no difference between university students from three different faculties who participated in sports in terms of the total scores of the SIAS and SIPAS (p\>0.05). It was determined that there was a significant difference between the students from three faculties in terms of the Anxiety of Losing Ability (ALA) parameter, which is one of the subscales of the SIAS (p\<0.05). In pairwise comparisons between the groups, a significant difference was found between the students of health sciences and medical faculties in the subscale of the SIAS-ALA (p=0.001). University students who participated in sports from all three faculties included in the study had normal levels of anxiety about sports injuries and high levels of sports injury awareness. High sports injury awareness of students participating in sports may be an important factor for injury prevention. Low levels of anxiety may also be associated with high levels of awareness.

Eligibility Criteria:
Inclusion Criteria:

* Volunteering to participate in the research
* To be a student in one of the Faculties of Sports Sciences, Health Sciences, Engineering and Medicine
* Participating in a regular sport branch

Exclusion Criteria:

* - Being diagnosed with a chronic disease or regular medication use
* Not being a student in one of the Faculties of Sports Sciences, Health Sciences, Engineering and Medicine
* Voluntary separation from employment
* Failure to complete the questionnaires to be applied within the scope of the study.
A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans

Within-subject, double-blind, placebo-controlled examination of opioid abuse potential in healthy individuals as a function of A118G SNP on the OPRM1 gene.

Participants completed a 5-day, within-subject, double-blind, placebo-controlled, randomized, human laboratory abuse potential trial. Healthy individuals were admitted to a residential research unit for 5 consecutive days. Blood samples were drawn for genome wide analyses using the Global Screening Array on day 1. Participants were administered an oral dose of the opioid hydromorphone (4mg) on day 2 of the study. Persons who did not evidence strong agonist effects then proceeded into the randomized period wherein they received 0mg, 2mg, and 8mg of oral hydromorphone on the remaining three study days. The order of dosing was randomized, with only 1 dose administered per day and all participants receiving 1 exposure to each dose. Outcomes were standard human abuse potential metrics, including self-reported drug effects and feeling high. Data were analyzed as a function of the A118SNP on the OPRM1 gene that codes for the mu opioid receptor. The overall aim was to determine whether signal for abuse potential among persons with no history of opioid misuse was associated with genotype.

Eligibility Criteria:
Inclusion Criterion:

1. Provide a urine sample that tests negative for opioids, methadone, buprenorphine, oxycodone, amphetamine, cocaine, and benzodiazepines
2. Negative ethanol breath test (0.000)
3. Aged 21-50
4. Deemed medically eligible to take hydromorphone

Exclusion Criterion:

1. Answer "yes" to question 1 of the Brief Pain Inventory (89) to assess the presence of chronic pain.
2. Current use of opioids or other medications for pain
3. Meet DSM-5 criteria for current or lifetime alcohol or drug use disorder (excluding nicotine)
4. Self-report any illicit drug use in the past 7 days
5. Self-report opioid use \>5 days in the past 30
6. Evidence of opioid physical dependence at screening or following 1st residential overnight (following confirmed opioid abstinence)
7. Allergy to hydromorphone or other opioid agonists
8. Experience an adverse event that warrants opioid antagonist treatment following 1st hydromorphone dose.
9. If female, not be pregnant or breastfeeding
10. Presence of any clinically significant medical (e.g., chronic renal insufficiency, history of myocardial infarction, seizure disorder) and/or psychiatric illness (e.g., schizophrenia, bipolar disorder) that may interfere with study participation.
11. BMI \>30 (obese category)